Floatz logo

Trastuzumab Deruxtecan

HER2 Low Breast Adenocarcinoma

Filipa Lynce, MDantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the HER2 Low Breast Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Inno-206
Virginia Commonwealth University
Phase 3BB
TRASTUZUMAB
Academic and Community Cancer Research United
Phase 3BB
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BB
Carboplatin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →